| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
25,980,000 |
| Market
Cap: |
77.68(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.62 - $5.66 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
268,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
9 |
| Total Buy Transactions |
0 |
0 |
0 |
9 |
| Total Shares Sold |
26,814 |
30,274 |
597,232 |
1,505,543 |
| Total Sell Value |
$78,297 |
$86,809 |
$1,362,931 |
$16,324,735 |
| Total People Sold |
5 |
6 |
8 |
12 |
| Total Sell Transactions |
5 |
6 |
22 |
82 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Thomas John |
|
– • – |
2025-06-06 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,000 |
480,501 |
|
- |
|
| Zindrick Thomas |
President and CEO |
• • – |
2025-05-12 |
4 |
S |
$2.92 |
$31,431 |
D/D |
(10,764) |
191,447 |
|
-8% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2025-05-12 |
4 |
S |
$2.92 |
$16,291 |
D/D |
(5,579) |
47,640 |
|
-8% |
|
| Ryder Sean |
General Counsel |
• – – |
2025-05-12 |
4 |
S |
$2.92 |
$13,067 |
D/D |
(4,475) |
47,621 |
|
-8% |
|
| Cappello Joseph |
VP, Pharmaceutical Development |
• – – |
2025-05-12 |
4 |
S |
$2.92 |
$13,832 |
D/D |
(4,737) |
52,266 |
|
-8% |
|
| Smalling Ralph |
Head of Regulatory |
• – – |
2025-05-12 |
4 |
S |
$2.92 |
$3,676 |
D/D |
(1,259) |
34,760 |
|
-8% |
|
| Cappello Joseph |
VP, Pharmaceutical Development |
• – – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
13,350 |
57,003 |
|
- |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
13,350 |
53,219 |
|
- |
|
| Smalling Ralph |
Head of Regulatory |
• – – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,172 |
36,019 |
|
- |
|
| Zindrick Thomas |
President and CEO |
• • – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
30,339 |
202,211 |
|
- |
|
| Ryder Sean |
General Counsel |
• – – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,708 |
52,096 |
|
- |
|
| Tyree James L |
|
– • – |
2024-12-30 |
4 |
S |
$2.46 |
$8,512 |
D/D |
(3,460) |
45,791 |
|
-16% |
|
| Smalling Ralph |
Head of Regulatory |
• – – |
2024-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
15,525 |
31,847 |
|
- |
|
| Ryder Sean |
General Counsel |
• – – |
2024-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
22,000 |
41,388 |
|
- |
|
| Zindrick Thomas |
President and CEO |
• • – |
2024-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
134,500 |
171,872 |
|
- |
|
| Zak Lourie S. |
Chief Financial Officer |
• – – |
2024-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
41,650 |
82,452 |
|
- |
|
| Cappello Joseph |
VP, Pharmaceutical Development |
• – – |
2024-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
29,000 |
43,653 |
|
- |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2024-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
29,000 |
39,869 |
|
- |
|
| Zak Lourie S. |
Chief Financial Officer |
• – – |
2024-12-16 |
4 |
S |
$2.34 |
$4,921 |
D/D |
(2,103) |
40,802 |
|
-26% |
|
| Cappello Joseph |
VP, Pharmaceutical Development |
• – – |
2024-12-16 |
4 |
S |
$2.34 |
$14,742 |
D/D |
(6,300) |
14,653 |
|
-26% |
|
| Smalling Ralph |
Head of Regulatory |
• – – |
2024-12-16 |
4 |
S |
$2.34 |
$5,873 |
D/D |
(2,510) |
16,322 |
|
-26% |
|
| Zindrick Thomas |
President and CEO |
• • – |
2024-12-16 |
4 |
S |
$2.34 |
$33,497 |
D/D |
(14,315) |
37,372 |
|
-26% |
|
| Szalay Aladar |
|
– – • |
2024-09-13 |
4 |
S |
$2.57 |
$84,946 |
I/I |
(33,080) |
599,821 |
|
-62% |
|
| Szalay Aladar |
|
– – • |
2024-09-12 |
4 |
S |
$2.73 |
$86,732 |
I/I |
(31,777) |
632,901 |
|
-26% |
|
| Tyree James L |
|
– • – |
2024-09-11 |
4 |
AS |
$2.60 |
$4,499 |
D/D |
(1,730) |
47,521 |
|
21% |
|
155 Records found
|
|
Page 1 of 7 |
|
|
0.06 (1.97%) 
